KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Depreciation & Amortization (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $4.7 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 7.19% year-over-year to $4.7 billion, compared with a TTM value of $4.7 billion through Dec 2025, up 7.19%, and an annual FY2025 reading of $4.7 billion, up 7.19% over the prior year.
  • Accumulated Depreciation & Amortization was $4.7 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $4.4 billion in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $5.6 billion in Q4 2023 and bottomed at $4.4 billion in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $5.1 billion, with a median of $5.2 billion recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization dropped 21.77% in 2024, then grew 7.19% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $5.2 billion in 2021, then grew by 5.29% to $5.5 billion in 2022, then increased by 2.16% to $5.6 billion in 2023, then fell by 21.77% to $4.4 billion in 2024, then increased by 7.19% to $4.7 billion in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for TEVA at $4.7 billion in Q4 2025, $4.4 billion in Q4 2024, and $5.6 billion in Q4 2023.